Recent studies indicate that the plasma contact system plays an important role in thrombosis, despite being dispensable for hemostasis. For example, mice deficient in coagulation factor XII (fXII) are protected from arterial thrombosis and cerebral ischemia-reperfusion injury. We demonstrate that selective reduction of prekallikrein (PKK), another member of the contact system, using antisense oligonucleotide (ASO) technology results in an antithrombotic phenotype in mice. The effects of PKK deficiency were compared to those of fXII deficiency produced by specific ASO-mediated reduction of fXII. Mice with reduced PKK had ~3-fold higher plasma levels of fXII, and reduced levels of fXIIa-serpin complexes, consistent with fXII being a substrate for activated PKK in vivo. PKK or fXII deficiency reduced thrombus formation in both arterial and venous thrombosis models, without an apparent effect on hemostasis. The amount of reduction of PKK and fXII required to produce an antithrombotic effect differed between venous and arterial models, suggesting that these factors may regulate thrombus formation by distinct mechanisms. Our results support the concept that fXII and PKK play important and perhaps non-redundant roles in pathogenic thrombus propagation, and highlight a novel, specific and safe pharmaceutical approach to target these contact system proteases.
INTRODUCTION
The blood coagulation system responds to vascular injury with local production of a clot formed of fibrin mesh and activated platelets. While this process is essential for hemostasis, dysregulated coagulation can lead to blood vessel occlusion (thrombosis), precipitating lifethreatening events such as myocardial infarction, stroke and venous thromboembolism. In the classical view of blood coagulation, thrombin generation and fibrin formation can be initiated by two distinct mechanisms referred to as the extrinsic and intrinsic pathways. 1, 2 The extrinsic pathway involves binding of plasma factor VIIa (fVIIa) to extravascular tissue factor (TF) at a site of vessel injury. 3 The first step in the intrinsic pathway requires the surface-dependent activation of plasma factor XII (fXII) to fXIIa in a process called contact activation. 4, 5 Contact activation involves two other proteins, prekallikrein (PKK) and high molecular weight kininogen (HK). HK serves as a docking molecule for PKK on the contact surface. PKK is cleaved by fXIIa to form the protease α-kallikrein, which in turn cleaves fXII to generate additional fXIIa.
Collectively, fXII, PKK and HK comprise the plasma contact system. FXIIa generated by contact activation can activate factor XI (fXI) to fXIa, triggering a series of proteolytic cleavage events that culminates in thrombin generation and fibrin clot formation.
While the contact system can clearly trigger coagulation in vitro, it is not required for hemostasis. Humans and other animals deficient in a contact activation protein are largely asymptomatic. 4, [6] [7] [8] However, the contact system may play an important role in thrombotic disease, as pharmacologic inhibition of fXIIa or ablation of the fXII or HK genes can protect mice from experimentally induced thrombosis in a variety of models. [9] [10] [11] [12] [13] Interestingly, fXII deficiency confers somewhat greater protection from thrombosis than fXI deficiency in some models, 11 implying that fXII may contribute to thrombus formation through additional pathways distinct from fXI-dependent intrinsic pathway activation. These data have generated interest in For personal use only. on . by guest www.bloodjournal.org From developing strategies to therapeutically inhibit fXIIa and contact activation to treat or prevent thromboembolic disorders.
Based on the clear importance of fXII to thrombus formation in mice, 11, 13 and the critical role of PKK in optimal activation of fXII during contact activation in human plasma, 14, 15 we hypothesized that PKK deficiency may have an antithrombotic effect in vivo. Here we show that antisense oligonucleotide (ASO) mediated selective knockdown of PKK or fXII in mice can inhibit thrombus formation in venous and arterial thrombosis models, without affecting hemostasis. We also provide evidence that PKK deficiency reduces fXII activation in vivo, consistent with PKK contributing to thrombus formation through activation of fXII. This is the first report describing antithrombotic affects of PKK depletion in vivo, as well the first demonstration of kallikrein-dependent fXII activation in vivo.
MATERIALS AND METHODS
Oligonucleotides. All oligonucleotides for PKK and fXII mRNA knockdown in vivo were 20 nucleotides in length and chemically modified with phosphorothioate in the backbone and 2'-Omethoxyethyl (MOE) on the wings with a central deoxy gap ("5-10-5" design). Oligonucleotides were synthesized and purified as previously described. 16 To identify potent PKK and fXII ASOs, ASOs were designed and tested in primary mouse hepatocytes for their ability to suppress mRNA levels of the respective target. From these experiments optimized ASOs were selected for evaluation in mice.
Animals and oligonucleotide dosing. Eight-week-old male BALB/c, C57BL/6 and Swiss Webster mice (Charles River Laboratories) were treated according to the indicated schedules.
The animals were housed in micro-isolator cages on a constant 12 hour light-dark cycle with controlled temperature and humidity and were given access to food and water ad libitum. All The amount of specific mRNA was analyzed using a StepOne™ Real-Time PCR System (Applied Biosystems, Life Technologies).
FXII and PKK immunoblot analysis. Plasma anticoagulated with sodium citrate was fractionated on 4-12% gradient SDS-polyacrylamide gels (Invitrogen) followed by immunoblotting with human fXII (Accurate Chemicals), mouse PKK (R&D Systems) or mouse α 2-antiplasmin (A2AP) (R&D Systems) antibodies. Blots were incubated with secondary fluorophore-labeled antibodies (LI-COR) and imaged on Odyssey Imager (LI-COR). PKK and fXII relative plasma protein levels were determined by densitometry analysis (ImageJ).
Plasma fXIIa-antithrombin complex ELISA. FXIIa-antithrombin plasma complex levels were measured by sandwich enzyme immunoassay. Briefly, assay plates were coated with antihuman fXII antibody (Accurate Chemicals) and blocked with 2% BSA prior to incubation with diluted mouse platelet poor plasma. After extensive washing, fXIIa-antithrombin complex was detected by incubation with HRP-conjugated antithrombin antibody (Enzygnost human TAT Micro ELISA kit, Siemens). Relative levels of fXIIa-antithrombin complex were calculated using serial dilutions of control mouse plasma as a standard. for Platelet Factor 4 (PF4) mRNA levels. PF4 mRNA levels were used to determine the effect of treatment on platelet deposition as a measure of thrombus formation. 19 PF4 mRNA levels in the IVC tissue exposed to FeCl 3 was normalized to non-exposed vena cava tissue.
Stenosis-induced IVC thrombosis. The St. Tomas model which uses a combination of reduced blood flow and endothelial damage, was used to study stenosis-induced IVC thrombosis. 18 Briefly, the IVC of male BALB/c mice anaesthetized with 2.5% inhalant isoflurane was exposed via a midline abdominal incision below the left renal vein, and separated from the abdominal aorta. A 6-0 silk tie (Ethicon, UK) was placed behind the vessel and a metal 4-0 suture (Ethicon, UK) was placed longitudinally over the IVC and tied over the top. Finally the metal 4-0 suture was removed. Next, two neurovascular surgical clips (Braun Medical) were applied at two separate positions below the ligation for twenty seconds each. The bowel was placed back into the abdominal cavity and the abdomen was closed. Twenty-four hours later IVC thrombi were collected and fixed in 10% formalin for 24 hours, photographed and weighed. 
RESULTS
Systemic delivery of ASO results in suppression of fXII and PKK levels in mice. The role of the intrinsic pathway and contact system in thrombosis in mice has been studied using a number of approaches, including knockout strategies and specific inhibitors. [9] [10] [11] 13, 20, 21 It is clear that fXII is involved in thrombus formation in these models. In vitro, PKK is required for optimal fXII activation, and we postulated that PKK may have a pro-thrombotic function in vivo.
As PKK knockout mice are not currently available, antisense technology was employed to explore the importance of PKK in thrombosis. The effect of PKK and fXII ASO treatment on expression of PKK and fXII mRNA in liver, and levels of PKK and fXII protein in plasma, are shown in Figure 1 . Systemic delivery (subcutaneous injections twice per week for 3 weeks) of ASO resulted in a dose-dependent reduction of target mRNA levels (92% and 96% reduction for PKK and fXII expression, respectively) at the highest tested ASO dose ( Figure 1A ). ASO treatment produced dose-dependent reduction of the target plasma protein, with maximum reductions of 83% and 85% for PKK and fXII, respectively ( Figure 1B, 1C and 1D ). Both PKK and fXII ASOs were highly specific for their targets, as demonstrated by unchanged liver mRNA It is important to note that the potencies of the ASOs were slightly different, with ED50 of 12 mg/kg/week for PKK ASO and 5 mg/kg/week for fXII ASO for liver reduction in mRNA levels, and 18 mg/kg/week and 7 mg/kg/week for plasma protein expression respectively.
FXII or PKK ASO-mediated knockdown stabilizes PKK or fXII proteins, respectively.
Plasma protein levels of PKK upon fXII depletion, and fXII upon PKK depletion, were significantly increased over basal levels ( Figure contributes to thrombosis in a number of models; however a role for PKK is not established. In addition, prior studies used homozygous fXII null (knockout) mice, thus the level of fXII required to support thrombosis has not been determined. Furthermore, we wanted to compare the activity of ASOs targeting the contact system to fXI inhibition, which we previously showed possesses remarkable anti-thrombotic activity in vivo. 18 The antithrombotic activity of fXII and PKK ASOs were compared in a widely used but constantly accumulated at the site of injury in an almost linear fashion ( Figure 5A and 5B, black line).
Both PKK and fXII ASO treatments at the highest dose (80 mg/kg/week) prevented fibrin formation, platelet aggregation and arterial occlusion over the time course of the study (70 minutes after FeCl 3 injury). In contrast to the venous thrombosis models, at lower doses of ASO, smaller reductions in PKK levels had a significantly smaller antithrombotic effect compared to similar reductions in fXII levels ( Figure 5D and 5E) . Indeed, all antithrombotic activity was lost for the PKK ASO at lower doses (40 mg/kg/week or less) ( Figure 5A ), while fXII ASO still effectively inhibited both fibrin generation and platelet aggregation ( Figure 5B ). Furthermore, fXII ASO had a more prominent inhibitory effect on fibrin generation than platelet activation ( Figure   5D , 5E and 5C).
In a video recording of arterial thrombus formation, we were able to see that small thrombi formed on the surface of the injured vessel after PKK or fXII ASO-mediated knockdown, but the development of thrombi was markedly delayed and their growth was severely compromised.
Continuous shedding of platelet aggregates from the site of the growing thrombi was detected, which prevented vessel occlusion. We have observed similar inhibition of thrombus growth in animals treated with fXI ASO, 18 suggesting that a significant component of fXII or PKK-initiated thrombosis involves fXI activation and subsequent thrombin generation. The similar sensitivity of fibrin formation to fXI or fXII ASO-mediated knockdown (Supplemental Figure 2G) supports the idea that activation of fXI is the primary mechanism by which fXII drives thrombus formation.
The effects of fXII and PKK ASO treatment on hemostasis. We have previously shown that inhibition of the intrinsic pathway by ASO-mediated knockdown of fXI results in a potent antithrombotic effect without compromising hemostasis, while antithrombotic treatment with low molecular weight heparin (Lovenox) or coumadin (Warfarin) caused pronounced bleeding. 18 We 1 2 were interested to see whether inhibition of the contact system proteases would also be safe with respect to bleeding. The effects of PKK or fXII ASO-mediated knockdown on bleeding were compared to that of prothrombin (fII) depletion in a tail vein bleeding assay ( Figure 6 ). As expected, reductions in fII levels resulted in significant blood loss. In contrast, PKK or fXII inhibition did not induce excessive bleeding even at the highest doses, consistent with the premise that contact proteases are not required for hemostasis.
DISCUSSION
Exposure of blood to artificial surfaces triggers reciprocal activation of the protease zymogens fXII and PKK. 5, 6 In vivo, substances such as collagen in basement membranes 22 and polyphosphates 23 released from platelet granules may serve as suitable surfaces to support contact activation. α-FXIIa and α-kallikrein, the proteases generated during contact activation, and their active degradation products β-fXIIa and β-kallikrein, may contribute to a number of host defense (inflammation, innate immunity, complement activation) and homeostatic (kinin generation, activation of the renin-angiotensin system) processes. 5, 24, 25 It is interesting to note that during vertebrate evolution the genes for fXII and PKK make their first appearances together in amphibians (they are not found in fish). 26 The fXII gene is a product of a duplication event involving the gene for hepatocyte growth factor activator (HGFA). Similarly, the apple domains that are a prominent feature of PKK are homologs of domains from the HGFA substrate hepatocyte growth factor. 26,27 Thus, from an evolutionary perspective, there are strong links between fXII and PKK. Nevertheless, the functional relationships between these proteins in vivo are not well understood, and mechanisms for PKK and fXII activation distinct from contact activation have been described. 28 
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In blood from most mammals, but not other vertebrate groups, induction of contact activation readily leads to thrombin generation. This is because fXIIa can activate fXI, a coagulation protease zymogen that is unique to placental and marsupial mammals. 26 Contact activationmediated fXI activation is required for clot formation in the activated partial thromboplastin time (aPTT) assay, a test widely used to assess hemostasis and monitor anticoagulant therapy in clinical practice. Despite the importance of fXII and PKK to the aPTT, it is clear that these proteins are not required for hemostasis. 29 However, the absence of bleeding symptoms with fXII and PKK deficiency does not establish that these proteases are not active at a site of injury.
Furthermore, recent evidence suggests that fXII makes important contributions to pathologic coagulation. Disruption of the fXII gene or specific fXIIa inhibitors protect rodents from thrombosis in a variety of experimental models, [9] [10] [11] 13, 21 raising the possibility that targeted inhibition of fXIIa may have a role in treating thromboembolism.
We reasoned that if contact activation was involved in fXII activation in vivo, then PKK should contribute to thrombus formation. Mice with targeted deletion of the PKK gene are not available, so we used ASO technology to create mice with low plasma PKK or fXII levels. At maximal doses, ASOs for murine PKK or fXII mRNA produced specific reductions of the appropriate mRNA in liver (95%), without affecting mRNA levels of other liver-derived coagulation factors.
While PKK ASO did not affect fXII mRNA levels, and fXII ASO did not affect PKK mRNA levels, depletion of either protein resulted in an increase in the plasma concentration of the other. At the highest level of fXII or PKK knockdown, plasma PKK and fXII protein levels, respectively, were ~3-fold greater than control. The decreased levels of fXIIa-or α-kallikrein-serpin complexes in plasmas of PKK and fXII ASO-treated mice, respectively, are consistent with reduced rates of fXII and PKK activation resulting in zymogen stabilization. Work from several groups suggests that the contact system in mice is active in normal health. 28, [30] [31] [32] Our data are consistent with this notion that the contact system "idles", resulting in basal rates of fXII and Both fXII and PKK ASO treatment produced impressive antithrombotic effects in mice, however, there were interesting differences in efficacy, depending on the model used. In FeCl 3 -induced and stenosis-induced venous thrombosis, PKK ASO produced a dose-dependent inhibition of thrombus growth that correlated linearly with reduction in plasma PKK. FXII, on the other hand, required a more significant reduction in plasma level to affect thrombus growth, particularly in the stenosis-based model, where fXII mRNA knockdown of >90% was required to protect mice from thrombus formation. This suggests that PKK may contribute to thrombus formation through one or more fXII-independent mechanisms, in addition to fXII-dependent pathways. However, this does not necessarily have to be the case. In contact activation in vitro, it is fXIIa that promotes clot formation through fXI activation, and it is probably the amount of fXIIa generated (and not the absolute amount of fXII) that is most important. In the venous thrombosis models, a reduction in fXII may not have as potent an effect on fXIIa generation (until the fXII level is <20% of normal) as loss of PKK-mediated activation of fXII, even though thrombus formation is ultimately mediated through fXIIa.
In contrast, in the FeCl 3 -induced arterial thrombosis model, a dose-response was observed with fXII ASO treatment, while PKK ASO produced an effect only at the highest concentration tested. This indicates relatively low PKK levels are required to support arterial thrombus formation. It is well established that reagents used to trigger contact activation in vitro differ in their sensitivities to PKK concentration. 32, 33 For example, aPTT assays that use micronized silica or ellagic acid to induce contact activation only detect PKK deficiency when the level drops to a few percent of normal. 33 A feature of PKK-deficient plasma that distinguishes it from plasmas deficient in other clotting factors is that the prolonged aPTT can be shortened by increased incubation time with the contact reagent. 29 This allows fXII to undergo autoactivation for a longer period of time,
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compensating for the loss of reciprocal fXII activation by α-kallikrein. The trigger for contact activation in the arterial thrombosis model may be a more efficient inducer of fXII autoactivation than the trigger in the venous thrombosis models, decreasing the amount of reciprocal activation by α-kallikrein required for thrombus formation. The fact that plasma fXII concentration rises with PKK ASO-mediated knockdown may also contribute to enhanced autoactivation.
In a recent study, Adams et al. reported that inhibition of plasma kallikrein activity in vivo by soybean trypsin inhibitor (SBTI), Pro-Phe-Arg-chloromethylketone (PFR-CK) or the plasma kallikrein inhibitor PKSI-527 shortened the time to arterial occlusion in a Rose Bengal-laser injury thrombosis model. 24 While none of these compounds are specific for α-kallikrein (they also inhibit fXIIa and/or fXIa), the authors felt that their activities were sufficiently specific to justify the conclusion that inhibiting α-kallikrein is prothrombotic. These results are at odds with reports describing an antithrombotic effect of PFR-CK in mouse arterial thrombosis and cerebral ischemia models. 13, 21 The reasons for the discrepancies are not clear. It is possible that there are fundamental differences between thrombosis models based on FeCl 3 or stenosis/stasis and the Rose Bengal-laser injury model that could account for the markedly different results.
However, our results with highly specific antisense oligonucleotides raise the distinct possibility that inhibitors such as SBTI and PFR-CK affect murine thrombosis models through mechanisms not directly related to α-kallikrein inhibition.
It is interesting to compare the effects of the antisense drugs targeting PKK and fXII with those previously reported for fXI ASO (Supplemental Figure 2) . 18 Results with the fXII ASO were roughly similar to those of the fXI ASO for both arterial and venous thrombosis models, perhaps with the fXI ASO showing somewhat greater potency. This is consistent with fXII contributing to thrombus formation through activation of fXI. These results are somewhat different from those 1 6 obtained with fXII and fXI knockout mice, where fXII deficiency conferred a greater antithrombotic effect than fXI deficiency. 11, 13 The discrepancy could be related to residual fXI and fXII protein and activity in the ASO-treated mice. Using intravitral microscopy, we noted that thrombus growth in animals treated with fXII or PKK ASOs, like those treated with fXI ASO, was severely compromised, exhibiting continuous disintegration under flow. The results are strikingly similar to those reported for arterial thrombi in fXII and fXI knockout mice, 13 and in baboons treated with anti-fXI antibodies. 34, 35 The underlying mechanism responsible for inhibition of thrombus growth has not been firmly established, but could include components of decreased platelet stimulation and fibrin formation as a result of reduced thrombin generation.
It is important to consider the relevance of our findings for development of antithrombotic strategies for human patients. A substantial amount of data indicates that fXI contributes to arterial and venous thromboembolism in humans, 4 but available information on the roles of fXII and PKK in these processes are not as clear. Indeed, for many years fXII deficiency was considered a prothrombotic state, dating back to the death of the index case for severe fXII deficiency from a pulmonary embolism. 36 Subsequent evaluations suggested other thrombotic risk factors are present in most fXII deficient patients with thrombosis, 37 and two case-controlled studies did not find a correlation between fXII deficiency and adverse outcome. 38, 39 However, the Study of Myocardial Infarction, Leiden (SMILE) project identified an inverse association between fXII levels and myocardial infarction risk, with an odds ratio for individuals in the highest quintile of fXII level of 0.4 compared with the lowest quintile. 40 This study examined fXII levels within the broad normal range and did not assess severe deficiency, which would be more relevant for predicting effects of therapeutic fXII inhibition. In a recent analysis of more than 8500 individuals in Austria, death from cardiovascular disease again was increased as fXII level decreased within the normal range. 41 However, mortality for those with severe fXII deficiency (1-10% of normal level) was similar to that for the population median, suggesting a 1 7 fundamental difference between severe and moderate deficiency. Elevated levels of fXIIa, on the other hand, have been associated with severity of atherosclerosis, increased risk for coronary heart disease, and increased recurrence of coronary events. [42] [43] [44] [45] [46] While this is consistent with the premise that fXIIa is prothrombotic in humans, it is not clear at this point if elevated fXIIa levels contribute to thrombotic events or are caused by them. When considering clinical data on fXII, it should be noted that antibodies to fXII and reduced fXII levels have been associated with antiphospholipid antibodies (APA) and the prothrombotic APA syndrome. 47, 48 APAs are relatively common in the general population, and it is possible they are more prevalent in patients with low to low-normal fXII levels, giving the false impression of an inherited deficiency. There is scant data on a role for PKK in human thromboembolism. Only ~75 cases for congenital PKK deficiency have been published, 7, 8, 29 precluding meaningful epidemiological analysis, and an association between elevated PKK levels and thrombosis has not been established. 49 Small molecule inhibitors, antibodies and ASOs targeting fXI or fXIa are currently under development for therapeutic use. Strategies based on these agents should be associated with a considerably lower bleeding risk than with currently used anticoagulant drugs. As fXI deficiency in humans is associated with a mild-to moderate hemorrhagic diathesis, fXII or PKK may be even more attractive targets because their inhibition may not cause any increase in risk of bleeding. Accordingly, the potent antithrombotic effects of fXII or PKK ASO-mediated knockdown in mice were not associated with increased bleeding in a tail-bleeding model. In comparison, prothrombin ASO-mediated knockdown, which is more comparable to anticoagulation with the vitamin K antagonist warfarin, was associated with significant bleeding.
However, there are several considerations remain to be carefully addressed if this approach progresses towards clinical evaluation. As we have mentioned, the contact system contributes to the aspects of host defense process (complement activation, generation of bradykinin and 1 8
antimicrobial peptides) as well as to the regulation of blood pressure through bradykinin. 5, 24, 25 Existing data and our current report suggest that the contact system "idles" in normal healthy subjects. 28, [30] [31] [32] Theoretically, basal levels of bradykinin generation may contribute to "normal" systemic blood pressure and thus, inhibition of the contact system could lead to hypertension. In preliminary experiments we have not detected significant differences in systemic blood pressure between normal and PKK ASO-treated mice (data not shown), however, a more rigorous evaluation of these possible effects should be carefully considered. Similarly, although no clinical data exists suggesting that fXII or PKK deficiency results in susceptibility to infectious diseases, these must also be carefully assessed during formal preclinical toxicology studies and throughout clinical evaluation.
In conclusion, the results of the present study support the premise that the contribution of fXII to thromboembolism involves a process similar or identical to contact activation, and indicate that PKK can be considered as an attractive target for treating or preventing thromboembolic disease. Effect of PKK (A) and fXII (B) antisense treatment at indicated doses on tail bleeding was evaluated in male BALB/c mice (n=10 per treatment group). FII ASO treatment at indicated dose was shown to cause increased bleeding and was used as reference drug (A and B). *P≤0.05, **P≤0.01 and ***P≤0.001 compared to untreated control.
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